[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Ko SF, Tsai YH, Huang HY, Ng SH, Fang FM, Tang Y, Sung MT, Hsieh MJ: Retrotracheal thymoma masquerading as esophageal submucosal tumor. World J Gastroenterol; 2005 May 28;11(20):3165-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrotracheal thymoma masquerading as esophageal submucosal tumor.
  • Esophagogram and endoscopy revealed submucosal mass effect on the upper esophagus.
  • Computed tomography and magnetic resonance imaging revealed an elongated mass in the retrotracheal region of the lower neck with extension to the posterior mediastinum.
  • Partial tumor resection and histopathological evaluation revealed a WHO type B2 thymoma.
  • Adjuvant radiation and chemotherapy were subsequently administered resulting in complete tumor regression.
  • To our knowledge, this is the first report of ectopic retrotracheal thymoma with clinical and imaging manifestations mimicking those for esophageal submucosal tumor.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Deglutition Disorders / etiology. Diagnosis, Differential. Hoarseness / etiology. Humans. Male

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918212.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305862
  •  go-up   go-down


2. Tobari S, Ikeda Y, Kurihara H, Takami H, Okinaga K, Kodaira S: Effective treatment with chemotherapy and surgery for advanced small cell carcinoma of the esophagus. Hepatogastroenterology; 2004 Jul-Aug;51(58):1027-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment with chemotherapy and surgery for advanced small cell carcinoma of the esophagus.
  • An abdominal computed tomography scan showed massive ascites, extensive paracardial mass, a large mass which invaded the pancreas, and a mass of multiple para-aortic lymphadenopathies which involved the superior mesenteric artery.
  • An upper gastrointestinal endoscopic study revealed an infiltrative, ulcerating tumor of the lower esophagus.
  • Histological study of the biopsy specimens from esophageal tumor showed small cell carcinoma.
  • After combination chemotherapy, an abdominal computed tomography scan showed a disappearance of asites, a partial response reduction of paragastric mass, peripancreatic mass and para-aortic lymphadenopathies.
  • Histological study of the biopsy specimens from esophageal tumor showed a viable small cell carcinoma.
  • In June 2001, the patient underwent lower esophagectomy and proximal gastrectomy combined with splenectomy and distal pancreatectomy through an abdominal approach.
  • Histological findings of the resected specimen showed that the esophageal tumor was a small cell carcinoma which invaded into the submucosal layer, and both paracardial and peripancreatic tumors, and all lymph nodes had no cancer cells.
  • The patient's postoperative recovery was uneventful and discharged without aggressive chemotherapy postoperatively.
  • However, he eventually died of progression of the metastasis 21 months after first detection of the carcinoma.
  • Patients with esophageal small cell carcinoma treated with surgery following chemotherapy and/or radiotherapy have been reported to survive longer than those treated with chemotherapy and/or radiotherapy.
  • Therefore, surgical resection may be recommended as the second therapy that occasionally produces long-term remission and possibly long-term survival for patients with small cell carcinoma of the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / surgery. Esophagectomy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239239.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Ichi T, Shiroma H, Arakaki K, Isa T: [A case of adenoid cystic carcinoma of the thoracic esophagus after neoadjuvant chemotherapy]. Nihon Shokakibyo Gakkai Zasshi; 2010 Feb;107(2):227-32
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenoid cystic carcinoma of the thoracic esophagus after neoadjuvant chemotherapy].
  • A 60-year-old man was admitted to our hospital with a tumor in the thoracic esophagus, and squamous cell carcinoma was detected by endoscopic biopsy.
  • On computed tomography, the tumor was suspected of having invaded adjacent organs by so the patient was given neoadjuvant chemotherapy consisting of low-dose CDDP and 5-FU.
  • After 2 courses of chemotherapy, a subtotal esophagectomy was performed.
  • The resected specimen showed no residual squamous cell carcinoma but another tumor was found in the submucosal layer which had a cribiform pattern in a solid nest.
  • The tumor cells were positive for S-100 protein and an Alcian-blue-positive substance in the gland, so the tumor was diagnosed as an adenoid-cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134125.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Saito Y, Andoh A, Hata K, Tsujikawa T, Ogawa A, Nakahara T, Kushima R, Fujiyama Y: Chemoradiation therapy followed by endoscopic submucosal dissection for esophageal cancer. Dig Dis Sci; 2008 Dec;53(12):3242-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation therapy followed by endoscopic submucosal dissection for esophageal cancer.
  • We performed chemoradiation therapy (CRT) followed by an endoscopic submucosal dissection (ESD) for three patients with esophageal cancer.
  • In all patients, CRT was effective in reducing tumor size, and the residual tumors were completely resected by ESD.
  • The combination of CRT plus subsequent ESD may be useful for treating patients with esophageal cancer who are not fit to undergo surgery.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Endoscopy. Humans. Male. Middle Aged. Mucous Membrane / drug effects. Mucous Membrane / radiation effects. Mucous Membrane / surgery. Radiotherapy

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2007 Sep;4(9):506-7 [17622234.001]
  • [Cites] Gut. 2001 Feb;48(2):225-9 [11156645.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):784-7 [17366797.001]
  • [Cites] Dis Esophagus. 2007;20(1):12-8 [17227304.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):688-94 [16713746.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2325-6 [10445587.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):352-61 [11900221.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):45-52 [17185197.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):507-12 [12297765.001]
  • [Cites] Dig Surg. 2007;24(2):88-95 [17446703.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):10-6 [17225940.001]
  • [Cites] Acta Oncol. 2006;45(8):1120-5 [17118849.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):205-8 [10680872.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):252-9 [17409865.001]
  • (PMID = 18470613.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Saito Y, Takisawa H, Suzuki H, Takizawa K, Yokoi C, Nonaka S, Matsuda T, Nakanishi Y, Kato K: Endoscopic submucosal dissection of recurrent or residual superficial esophageal cancer after chemoradiotherapy. Gastrointest Endosc; 2008 Feb;67(2):355-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection of recurrent or residual superficial esophageal cancer after chemoradiotherapy.
  • BACKGROUND: Treatment of local recurrent or residual superficial esophageal squamous-cell carcinoma (SCC) with conventional EMR often results in a piecemeal resection that requires further intervention.
  • OBJECTIVE: The aim of this study was to evaluate the efficacy of endoscopic submucosal dissection (ESD).
  • PATIENTS: Between January 2006 and September 2006, 4 local recurrent or residual superficial esophageal SCCs were treated by ESD.
  • After injection of glycerol into the submucosal (sm) layer, a circumferential incision was made, and an sm dissection was performed.
  • All lesions were determined to be intramucosal or sm superficial, without lymph-node metastasis by EUS before treatment.
  • MAIN OUTCOME MEASUREMENTS: Tumor size, en bloc resection rate, tumor-free lateral margin rates, and complications were recorded.
  • RESULTS: All 4 ESD cases were successfully resected en bloc, and the tumor-free lateral margin rate was 75% (3/4) by histopathology examination.
  • The mean tumor size of the resected specimens was 35 mm (range, 15-50 mm).
  • CONCLUSIONS: ESD for recurrent or residual superficial esophageal tumors after chemoradiotherapy achieves the goal of an en bloc resection, with a low rate of incomplete treatment without any greater risk than the EMR technique.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery
  • [MeSH-minor] Combined Modality Therapy. Dissection / methods. Endoscopy, Gastrointestinal. Humans. Mucous Membrane. Recurrence

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226703.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Takada J, Watanabe K, Kuraya D, Kina M, Hayashi S, Hamada H, Katsuki Y: [Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2451-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer].
  • INTRODUCTION: The prognosis of type 4 advanced gastric cancer is extremely poor, even the use of multidisciplinary treatment cannot provide satisfactory results.
  • Presented here is a case of highly advanced gastric cancer in which preoperative chemotherapy was effective and resection possible.
  • Type 4 advanced gastric cancer was strongly suspected.
  • Abdominal CT revealed no hepatic mass, but overall thickening of the gastric wall was noticeable and the lymph nodes in the area of the lesser curvature of the stomach and celiac artery were identified.
  • TREATMENT: Because of gastric cancer with suspected invasion of the left hepatic lobe and pancreas, it was decided to perform preoperative chemotherapy (S-1 + CDDP) and then perform a total gastrectomy.
  • Only scarring in the body and antrum was found, the enlargement was greatly reduced and visual inspection revealed no esophageal infiltration.
  • These findings showed preoperative chemotherapy to be effective.
  • Following the chemotherapy, a total gastrectomy in addition to splenectomy and cholecystectomy were performed.
  • Histopathological findings showed MLU, type 5, approx.
  • Along with the formation of fibrous scar tissue, an invasive growth of por 2 poorly differentiated adenocarcinoma was found from the submucosal layer to just beneath the serosal layer.
  • Therapeutic effect of the chemotherapy was Grade 2.
  • Post operative S-1 + CDDP was begun but nausea developed and S-1 was reduced.
  • Because of a decrease of neutrophils and nausea, the therapy was changed to UFT.
  • CONCLUSION: Preoperative chemotherapy (S-1 + CDDP) is a therapy which shows promise in reducing tumor size even in highly advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Gastrectomy. Humans. Middle Aged. Oxonic Acid / administration & dosage. Preoperative Period. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224603.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Okamura H, Fujiwara H, Suchi K, Okamura S, Umehara S, Konishi H, Todo M, Kubota T, Ichikawa D, Kikuchi S, Okamoto K, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Otsuji E: [Surgically resected local recurrence after endoscopic submucosal dissection of esophageal cancer--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2448-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgically resected local recurrence after endoscopic submucosal dissection of esophageal cancer--a case report].
  • We report a case of surgically resected esophageal cancer which was locally recurred after endoscopic submucosal dissection.
  • A 66-year-old man was admitted to our hospital because of further examination and a treatment of superficial esophageal cancer.
  • A type 0-IIb+IIa cancer occupying the whole circumference of the lumen of the middle to lower esophagus was revealed.
  • Endoscopic submucosal dissection (ESD) was performed.
  • Pathological diagnosis was squamous cell carcinoma, moderately differentiated, the depth of tumor invasion was T1a-LPM.
  • After that, endoscopic balloon dilatation of the esophageal stenosis was performed repeatedly for about one year.
  • Then, he was diagnosed as the local recurrence of the squamous cell carcinoma of the esophagus.
  • After the operation, he is receiving adjuvant chemotherapy and alive without recurrence.
  • When endoscopic resection of the esophageal cancer is performed to the lesion, which relatively indicated to endoscopic resection or outside the guideline criteria for endoscopic resection, it is important that we choose the appropriate treatment protocol obtaining an informed consent from the patient sufficiently.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Esophagoscopy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Recurrence, Local / surgery. Reoperation

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Kagaya H, Kitayama J, Hidemura A, Kaisaki S, Ishigami H, Takei J, Kanazawa T, Nagawa H: Metastatic esophageal tumor from cecal carcinoma. Jpn J Clin Oncol; 2007 Aug;37(8):628-31
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic esophageal tumor from cecal carcinoma.
  • A 55-year-old man developed progressive dysphagia 14 months after palliative colectomy and subsequent systemic chemotherapy for advanced cecal cancer with carcinomatosis peritonei.
  • Radiologic and endoscopic examinations suggested a submucosal tumor in the lower esophagus causing a severe luminal stricture.
  • The prosthesis was effective for several months, but ingrowth of the tumor caused re-stricture of the esophagus.
  • The pathological appearance of the tumor was compatible with the metastasis of cecal cancer.
  • Our case suggests that a surgical approach can be considered as a therapeutic method for metastatic esophageal tumor, even in patients with advanced cancer, as long as the primary tumor is satisfactorily controlled.
  • [MeSH-major] Cecal Neoplasms / pathology. Esophageal Neoplasms / secondary
  • [MeSH-minor] Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Humans. Male. Middle Aged. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804397.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


9. Sentani K, Nakanishi Y, Ojima H, Hamaguchi T, Shimoda T: Esophageal squamous cell carcinoma presenting with systemic arterial embolism. Pathol Int; 2007 Feb;57(2):96-100
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal squamous cell carcinoma presenting with systemic arterial embolism.
  • Acute arterial occlusion as a result of embolization from a malignant tumor is rare and infrequently reported.
  • Subsequent upper gastrointestinal endoscopy showed superficial esophageal cancer in the thoracic esophagus.
  • Although scheduled to undergo chemotherapy, he died of acute pneumonia on the 81st day from onset.
  • Autopsy showed superficial esophageal cancer, measuring 1.5 cm in diameter, and widespread tumor extension into arterial vessels such as the left femoral artery, the superior mesenteric artery, bilateral intrapulmonary arteries and veins such as bilateral brachiocephalic vein to the supra vena cava, despite small tumor size and shallow tumor invasion depth of the submucosal layer.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Femoral Artery / pathology. Humans. Male. Mesenteric Artery, Superior / pathology. Pulmonary Artery / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300674.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 17
  •  go-up   go-down


10. Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S: Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1106-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma.
  • PURPOSE: In 1991, we started a clinical prospective trial for operable esophageal carcinoma, foreseeing organ preservation, to assess the treatment results after definitive chemoradiotherapy (CRT) for clinical Stage I (T1N0M0) esophageal cancer.
  • Tumor depth was mucosal cancer (T1a) in 23 and submucosal cancer (T1b) in 40.
  • CRT consisted of 55-66 Gy/50-60 fractions (median, 59.4 Gy); from 1 to 3 cycles (median, 2) of concurrent chemotherapy (Cisplatin and 5-fluorouracil), followed by high-dose-rate intraluminal brachytherapy 10-12 Gy/2-3 fractions.
  • Esophageal fistula as a late toxicity occurred in 2 patients (G4: 1; G5: 1), and esophageal stricture requiring a liquid diet occurred in 2 patients.
  • CONCLUSION: We confirmed that patients with T1N0M0 esophageal carcinoma had their esophagus preserved in 89.2% of cases after definitive CRT, and the survival rates were equivalent to those of previous reports of surgery.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy / adverse effects. Brachytherapy / methods. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Esophagectomy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504758.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Yoshii T, Tamai S, Aoyama N, Minamide J, Takagi S, Motohashi O, Nakayama N, Nishimura K, Takata K, Kameda Y: Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer.
  • : e15569 Background: When a tumor invades to the muscularis mucosa or submucosal layer (T1a-MM or T1b, in Japan), cSt I esophageal cancer(EC) has 10-50%.
  • Surgery, though very invasive, is the standard radical therapy for the patients(pts.) with such stage EC.
  • Endoscopic mucosal resection (EMR), which conserves the esophagus, is a minimally invasive and attractive therapeutic modality for such pts.
  • RESULTS: Patients decided on the following treatments immediately after EMR based on informed consent and their general condition; 2 underwent surgery, one underwent prophylactic chemotherapy(CHT) and 41 selected follow-up without any additional therapy.
  • Median follow-up time was 1542days (375-3786).
  • 5 developed LNM.
  • 8 and 6 pts. developed metachronous EC and local recurrence, respectively.
  • CONCLUSIONS: EMR is a very useful therapeutic modality for cSt I EC, not only for local control but also as a clinically sufficient treatment; especially in pts. with severe concurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962323.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kobayashi N, Ohbu M, Kuroyama S, Kikuchi S, Shimao H, Mitomi H, Kakita A: Alpha-Fetoprotein-producing esophageal adenocarcinoma: report of a case. Surg Today; 2001;31(10):915-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-Fetoprotein-producing esophageal adenocarcinoma: report of a case.
  • Alpha-fetoprotein (AFP)-producing esophageal tumors are extremely rare.
  • We report herein the case of a 51-year-old man found to have an AFP-producing adenocarcinoma arising from esophageal proper mucosa.
  • The patient presented for investigation of dysphagia, and esophagogram and endoscopy revealed a lesion about 2 cm in size with a depressed center surrounded by low nodular protrusions in the lower esophagus.
  • The tumor had infiltrated the submucosal layer, but there was no evidence of lymphatic or venous invasion.
  • Immunohistochemical study revealed tumor cells positive for AFP.
  • An elevated AFP level 2 years after the operation led us to suspect tumor recurrence; however, diagnostic imaging studies showed no evidence of a recurrence or metastases.
  • The serum AFP levels responded well to chemotherapy with transient decreased levels, but continued to rise until finally, 5 years after the operation, adenocarcinoma cells were detected in the pleural effusion.
  • Thus, careful monitoring of the serum AFP levels at regular intervals could be a useful marker to indicate recurrence of esophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. alpha-Fetoproteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11759890.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Kawamoto M, Kunisaki C, Kunihiro O, Kamiya N, Moriwaki Y, Akiyama H, Shimada H, Kono N, Nakatani Y, Kunisaki R: Basaloid cell carcinoma of the esophagus with a metastatic neck tumor of unknown origin: report of a case. Surg Today; 2003;33(7):529-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid cell carcinoma of the esophagus with a metastatic neck tumor of unknown origin: report of a case.
  • A 51-year-old man was admitted to our hospital with a tumor in the right anterior region of his neck.
  • Further investigations, including upper gastro-intestinal series and endoscopy, showed two flush lesions in the middle and lower thoracic esophagus.
  • He underwent esophagectomy with three-field lymph node dissection, including the neck tumor.
  • Histological findings revealed that the tumor in the middle thoracic esophagus was moderately differentiated SCC, and that the other tumor below it was basaloid cell carcinoma (BCC).
  • The depths of invasion were to the lamina propria mucosae for the former and to the submucosal layer for the latter.
  • A diagnosis of poorly differentiated SCC of unknown origin was made for the neck tumor.
  • Postoperative recombinant chemotherapy with cisplatin and 5-fluorouracil was given for the unknown primary site, which we still have not identified.
  • No recurrence of the esophageal cancer has been detected.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / pathology. Esophageal Neoplasms / pathology. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506999.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Bibeau F, Chateau MC, Guiu M, Assenat E, Azria D, Lavaill R, Ychou M, Boissière-Michot F: Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour. Virchows Arch; 2008 Jan;452(1):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour.
  • Most Barrett's oesophagus-associated cancers are adenocarcinomas which occur in a pure form.
  • They are rarely combined with another type of malignancy, such as endocrine tumours.
  • We report a case of composite SmCC and adenocarcinoma in the setting of a Barrett's oesophagus, in a 54-year-old man.
  • This tumour was identified on a surgical specimen after neoadjuvant treatment with radiotherapy and 5-FU-Cis-platin based chemotherapy.
  • In our case, the origin of the SmCC component could be explained by the numerous chromogranin A-positive cells observed in the Barrett's oesophagus or by the potential progenitor cells that may be located in the submucosal oesophageal gland ducts and the Barrett's metaplasia.
  • Our report is thus indicative of the high and totipotential risk of Barrett's oesophagus.
  • Moreover, it is particular because of its favourable behaviour, with a 6-year disease-free survival, after neoadjuvant chemoradiation, surgery and postoperative chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chromogranin A / metabolism. Combined Modality Therapy. Disease-Free Survival. Esophagectomy. Esophagus / pathology. Esophagus / surgery. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2005 Aug;206(4):388-94 [15926200.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):465-75 [15297939.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1205-11 [10810423.001]
  • [Cites] World J Gastroenterol. 2004 Dec 15;10(24):3680-2 [15534932.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):980-7 [10987260.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1424-8 [11023106.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):596-7 [11515903.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Arch Pathol. 1974 Aug;98(2):87-9 [4134908.001]
  • [Cites] J Clin Gastroenterol. 1997 Mar;24(2):116-9 [9077732.001]
  • [Cites] Ann Thorac Surg. 1989 Mar;47(3):477-80 [2539065.001]
  • [Cites] J Pathol. 1985 Jul;146(3):227-34 [2863340.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1108-15 [14652811.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):215-23 [15043311.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):216-21 [10029452.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):284-7 [10587033.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2002 Dec;50(12):537-40 [12561099.001]
  • [Cites] Am J Clin Oncol. 2000 Dec;23(6):554-8 [11202794.001]
  • [Cites] Surgery. 1994 Feb;115(2):176-81 [8310406.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jan;101(1):100-7 [1702494.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1685-7 [11079026.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • (PMID = 18008084.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A
  •  go-up   go-down


16. Yoshida M, Nishikawa Y, Yamamoto Y, Doi Y, Tokairin T, Yoshioka T, Omori Y, Watanabe A, Takahashi N, Yoshioka T, Miura I, Sawada K, Enomoto K: Mast cell leukemia with rapidly progressing portal hypertension. Pathol Int; 2009 Nov;59(11):817-22
Genetic Alliance. consumer health - Portal hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy with cytosine arabinoside and idarubicin was ineffective and the patient died of multi-organ failure with rapidly progressing hepatosplenomegaly and large-volume ascites 3 months after admission.
  • At autopsy the bone marrow, spleen, liver, and lymph nodes were extensively infiltrated by atypical tumor cells with occasional bi- or multi-lobated nuclei.
  • Ascites (2200 mL) and non-ruptured esophageal varices with submucosal hemorrhage indicated the presence of severe portal hypertension.
  • Although there was no evidence of liver cirrhosis, the hepatic sinusoids were clogged with tumor cells, with a tendency to be more severe in the perivenular areas, and the lumens of central veins were obliterated by tumor cell infiltration.

  • Genetic Alliance. consumer health - Leukemia, mast-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883434.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Sumi M, Takaku T, Iguchi T, Ishii Y, Katagiri T, Tauchi T, Serizawa H, Mukai K, Ohyashiki K: [Primary diffuse large B-cell lymphoma of the esophagus]. Rinsho Ketsueki; 2004 Sep;45(9):1067-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the esophagus].
  • A 64-year-old man with primary esophageal lymphoma suffered from dysphagia.
  • An upper gastrointestinal examination revealed a partly ulcerated submucosal tumor in the upper portion of the esophagus.
  • Histopathological and immunohistological examination of endoscopic biopsy specimens showed diffuse large B-cell lymphoma of the immunoblastic type.
  • Improvement of the dysphagia and esophageal findings were noted after chemotherapy and radiotherapy.
  • A review of the literature indicated that primary esophageal lymphomas account for less than 1% of all gastrointestinal lymphomas, and less than 0.1% of all malignant lymphomas.
  • Because of the rarity of primary esophageal lymphoma, its clinical and biological characteristics are not currently well known.
  • It is important to accumulate information on, and to further investigate patients with, primary esophageal lymphoma.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510839.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Horváth Ors P, Papp A, Kalmár K, Cseke L, Yousuf AF, Esik O: [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept]. Magy Seb; 2006 Oct;59(5):333-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept].
  • Formerly the treatment of gastrointestinal cancers was exclusively surgical.
  • Though the results were improved by increased radicality, the real progress was achieved by the introduction of multimodal therapy, particularly by the neoadjuvant concept.
  • The basic prerequisite for neoadjuvant treatment is precise staging and risk assessment.
  • (1) Early cancers, confined to the mucosal and submucosal layers, are approached with primary surgery. (2) Systemically metastasized tumors receive merely palliative treatment. (3) Locally advanced cancers are treated by neoadjuvant therapy.
  • Due to neoadjuvant treatment the tumor can be downsized (or downstaged) in some patients.
  • These are the responders benefiting from the therapy, because of the increased RO-resection rate, decreased recurrence rate and improved survival.
  • Neoadjuvant treatment considerably improved the chance for cure for patients with gastrointestinal cancers, thus this method became an evidence based treatment for locally advanced gastrointestinal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy / adverse effects. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Remission Induction. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201341.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 30
  •  go-up   go-down


19. Tsutsui M, Yoshino S, Sakamoto K, Oka M: [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2351-3
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imatinib is a standard treatment for metastatic GIST.
  • Surgery is an optional treatment for local recurrence and resectable liver metastasis.
  • A 63-year-old man underwent a surgery for undifferentiated esophageal cancer and simultaneously was diagnosed a rectal submucosal tumor of 3 cm by digital examination in 2001.
  • After 2 years, he underwent Miles' operation because of an increase of the rectal submucosal tumor.
  • Combined modality therapy with surgery and chemotherapy for the metastatic GIST may contribute to a long-term survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pleural Neoplasms / secondary. Pyrimidines / therapeutic use. Rectal Neoplasms / therapy
  • [MeSH-minor] Administration, Oral. Benzamides. Chemotherapy, Adjuvant. Humans. Imatinib Mesylate. Male. Mediastinum. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037419.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


20. Foroulis CN, Thorpe JA: Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. Eur J Cardiothorac Surg; 2006 Jan;29(1):30-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.
  • OBJECTIVE: Esophagectomy is the standard treatment for high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC) arising within Barrett's esophagus.
  • Results of photodynamic therapy (PDT) were retrospectively studied to evaluate the effectiveness of PDT in ablating HGD and/or IMC complicating Barrett's esophagus.
  • METHODS: Thirty-one patients unfit for or refusing esophagectomy (male: 20, mean age: 73.4+/-9.3 years) underwent Porfimer sodium PDT ablation of their HGD (15 patients), HGD plus IMC (10 patients) or submucosal/limited T2 adenocarcinoma (6 patients).
  • The long-term results were (a) for HGD/IMC: initial complete response (endoscopic and histologic absence of HGD-IMC) to PDT was observed in 80.95% of patients, partial response (no endoscopic abnormality, residual IMC-HGD on biopsy) in 9.52%, no response in 9.52% (the recurrence rate after an initial complete response was 17.64%) and (b) for T1b/limited T2 tumors: two patients died from cancer after 24 and 46 months, no evidence of tumor was found in two patients after 12 and 19 months and tumor recurrence was seen in two after 15 and 17 months.
  • CONCLUSIONS: PDT is effective in ablating HGD/IMC complicating Barrett's esophagus in the majority of cases, while it also seems to be quite effective in treating T1b/limited T2 carcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Photochemotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Dihematoporphyrin Ether / therapeutic use. Esophagoscopy / methods. Female. Humans. Male. Middle Aged. Mucous Membrane / pathology. Patient Satisfaction. Photosensitizing Agents / therapeutic use. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337389.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down






Advertisement